ProtoKinetix Inc
protokinetix.comProtoKinetix Inc (OTC: PKTX) is a development-stage medical research company that is developing proprietary compounds under a royalty agreement with the University of Alberta (agreement dated April 8, 2015). The company generates no commercial revenue. As of December 31, 2024, PKTX reported a negative working capital equity deficit of $127,694, a $4,697 shortfall in cash, and negative $3,647 in total current assets, funding operations entirely through private placements of common stock. Between March 29, 2024 and December 26, 2024, the company raised $240,000 in gross proceeds by issuing 24,000,000 shares at $0.01 per share to accredited investors. Net cash used in operating activities was $223,050 for the year ended December 31, 2024, down from $375,989 in 2023, driven by reduced spending on web marketing, news releases, social media, and new research. CEO and Chairman Clarence E. Smith signed the annual report on March 28, 2025. The company carries intangible assets in the form of patents, subject to annual impairment testing.
Products & Services
Proprietary medical research compounds developed under a royalty agreement with the Governors of the University of Alberta (dated April 8, 2015). Patent portfolio held as intangible assets, with impairment assessed annually.
Revenue Model
No commercial revenue as of December 31, 2024. Operations are funded exclusively through equity issuances via private placements to accredited investors under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Customers & Markets
No commercial customers as of December 31, 2024. End market is medical/biomedical research. No customer revenue disclosed in the FY2024 10-K.
Geographic Exposure
Incorporated in the United States. Research partnership with the University of Alberta in Canada. Audited by Davidson & Company LLP, Vancouver, BC, Canada.
Financial Snapshot
Loading...
